Serum Erythropoietin as Prognostic Marker in Myelodysplastic Syndromes

Introduction: This myelodysplastic syndromes are a heterogeneous entity characterized by dysplasia, hypercellular bone marrow, cytopenias and risk of transformation to acute leukaemia. Prognostic factors, such as bone marrow fibrosis, lactate dehydrogenase and β2-microglobulin elevation have been de...

ver descrição completa

Detalhes bibliográficos
Autor principal: Cortesão, Emília (author)
Outros Autores: Tenreiro, Rita (author), Ramos, Sofia (author), Pereira, Marta (author), César, Paula (author), Carda, José P. (author), Gomes, Marília (author), Rito, Luís (author), Magalhães, Emília (author), Gonçalves, Ana C. (author), Silva, Nuno C. e (author), Geraldes, Catarina (author), Pereira, Amélia (author), Ribeiro, Letícia (author), Nascimento Costa, José M. (author), Ribeiro, Ana B. Sarmento (author)
Formato: article
Idioma:por
eng
Publicado em: 2015
Assuntos:
Erythropoietin
Myelodysplastic Syndromes
Prognosis.
Eritropoietina
Prognóstico
Síndrome Mielodisplásica.
Texto completo:https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/6518
País:Portugal
Oai:oai:ojs.www.actamedicaportuguesa.com:article/6518

Texto Completo

https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/6518

Registos relacionados